Fine-Tuning Stem Cell Therapy to Repair the Heart
|
By LabMedica International staff writers Posted on 27 Mar 2013 |
Stem cells have the potential to grow into a range of cell types, including heart cells. Researchers are now trying to refine the process of repairing and regenerating heart tissue damaged by a heart attack with stem cells.
A recent study from Cedars-Sinai Heart Institute (Los Angeles, CA, USA) suggests that stem cells may, undeniably, heal damaged hearts. The researchers treated 17 heart attack survivors with an infusion of stem cells taken from their own hearts. One year later, the amount of scar tissue had shrunk by about 50%. These findings look dramatic, but investigators are wondering if they an indication that they are close to perfecting stem cell therapy.
“This is a field where, depending on which investigator you ask, you can get incredibly different answers,” Dr. Richard Lee, professor of medicine at Harvard Medical School (Boston, MA, USA), and a leading specialist on stem cell therapy, reported in the March 2013 issue of Harvard Women’s Health Watch. “The field is young. Some studies show only modest or no improvement in heart function, but others have shown dramatically improved function. We’re waiting to see if other doctors can also achieve really good results in other patients.”
New research is generating contrary findings in part, because researchers use diverse approaches to harvest and use stem cells. Some are gathered from the bone marrow of donors, others from the recipient’s own heart. It is not evident which approach works optimally. “Some investigators think this is just a few years away,” concluded Dr. Lee. “And then there are others who feel that there is much more work to be done.”
Presently, stem cell therapy is available only to individuals who participate in a research trial.
Related Links:
Cedars-Sinai Heart Institute
Harvard Medical School
A recent study from Cedars-Sinai Heart Institute (Los Angeles, CA, USA) suggests that stem cells may, undeniably, heal damaged hearts. The researchers treated 17 heart attack survivors with an infusion of stem cells taken from their own hearts. One year later, the amount of scar tissue had shrunk by about 50%. These findings look dramatic, but investigators are wondering if they an indication that they are close to perfecting stem cell therapy.
“This is a field where, depending on which investigator you ask, you can get incredibly different answers,” Dr. Richard Lee, professor of medicine at Harvard Medical School (Boston, MA, USA), and a leading specialist on stem cell therapy, reported in the March 2013 issue of Harvard Women’s Health Watch. “The field is young. Some studies show only modest or no improvement in heart function, but others have shown dramatically improved function. We’re waiting to see if other doctors can also achieve really good results in other patients.”
New research is generating contrary findings in part, because researchers use diverse approaches to harvest and use stem cells. Some are gathered from the bone marrow of donors, others from the recipient’s own heart. It is not evident which approach works optimally. “Some investigators think this is just a few years away,” concluded Dr. Lee. “And then there are others who feel that there is much more work to be done.”
Presently, stem cell therapy is available only to individuals who participate in a research trial.
Related Links:
Cedars-Sinai Heart Institute
Harvard Medical School
Latest BioResearch News
- Study Reveals Diagnostic and Therapeutic Target in Rare Pancreatic Tumors
- Researchers Identify Survival Pathway Undermining Targeted Cancer Drugs
- Large-Scale Study Maps DNA Damage Signatures Across Multiple Cancers
- Study Identifies Distinct Immune Signatures to Early Depression and Psychosis
- Genetic Mutation Behind Aggressive Adult Leukemia Offers Treatment Clues
- Disease Gene Discovery Advances Diagnosis of Rare Movement Disorders
- Genetic Discovery Could Improve Diagnosis of Drug-Resistant Epilepsy
- Genetic Discovery May Improve Diagnosis of Rare Dementia Subtype
- Mass Spectrometry Technique Detects Protein and Sugar Changes in Neurodegeneration
- Barcoded DNA Sheds Light on Hidden Complexities in Breast Cancer Detection
- CRISPR-Based Platform Pinpoints Drivers of Acute Myeloid Leukemia in Patient Cells
- Protective Brain Protein Emerges as Biomarker Target in Alzheimer’s Disease
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read moreMolecular Diagnostics
view channel
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
New AI Tool Improves Detection of Genetic Causes in Rare Disorders
Families affected by rare diseases often endure years of inconclusive testing and fragmented referrals before a definitive diagnosis. Despite broad access to genomic sequencing, many patients remain undiagnosed,... Read moreHematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read moreImmunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read moreMicrobiology
view channel
New Bacterial Target Identified for Early Detection of Noma
Noma is a rapidly progressing orofacial infection that begins as gingivitis and can destroy oral and facial tissues, primarily affecting young children living in extreme poverty. Without treatment, it... Read more
Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
Streptococcus dysgalactiae subspecies equisimilis (SDSE) infections are increasing worldwide and include variants that may lead to severe disease. Researchers now report that whole-genome sequencing of... Read morePathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more








